Cargando…

Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study

BACKGROUND: It is well established that lipoprotein(a)[Lp(a)] play a vital role in atherosclerosis. Whether Lp(a) can predict recurrence of cardiovascular events (CVEs) in prior CVEs patients is still unclear. We aim to investigate its association with subsequent long-term adverse events in this hig...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Na, Yao, Yi, Jiang, Lin, Xu, Jingjing, Wang, Huanhuan, Song, Ying, Yang, Yuejin, Xu, Bo, Gao, Runlin, Yuan, Jinqing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682694/
https://www.ncbi.nlm.nih.gov/pubmed/36414932
http://dx.doi.org/10.1186/s12959-022-00424-9
_version_ 1784834907521941504
author Xu, Na
Yao, Yi
Jiang, Lin
Xu, Jingjing
Wang, Huanhuan
Song, Ying
Yang, Yuejin
Xu, Bo
Gao, Runlin
Yuan, Jinqing
author_facet Xu, Na
Yao, Yi
Jiang, Lin
Xu, Jingjing
Wang, Huanhuan
Song, Ying
Yang, Yuejin
Xu, Bo
Gao, Runlin
Yuan, Jinqing
author_sort Xu, Na
collection PubMed
description BACKGROUND: It is well established that lipoprotein(a)[Lp(a)] play a vital role in atherosclerosis. Whether Lp(a) can predict recurrence of cardiovascular events (CVEs) in prior CVEs patients is still unclear. We aim to investigate its association with subsequent long-term adverse events in this high-risk population. METHODS: A total of 4,469 patients with prior CVEs history after PCI were consecutively enrolled and categorized according Lp(a) values of < 10 (low), 10 to 30 (medium), and ≥ 30 mg/dL (high). The primary endpoint was MACCE, a composite of all-cause death, myocardial infarction, stroke and unplanned revascularization. RESULTS: During an average of 5.0 years of follow-up, 1,078 (24.1%) and 206 (4.6%) patients experienced MACCE and all-cause death with 134 (3.0%) of whom from cardiac death. The incidence of MACCE, all-cause death and cardiac death were significantly higher in the high Lp(a) group (p < 0.05). After adjustment of confounding factors, high Lp(a) level remained an independent risk factor for MACCE (adjusted HR 1.240, 95%CI 1.065–1.443, p = 0.006), all-cause death (adjusted HR 1.445, 95%CI 1.023–2.042, p = 0.037) and cardiac death (adjusted HR 1.724, 95%CI 1.108–2.681, p = 0.016). This correlation remained significant when treated as a natural logarithm-transformed continuous variable. This finding is relatively consistent across subgroups and confirmed again in two sensitivity analyses. CONCLUSIONS: Our present study confirmed that Lp(a) was an independent predictor for recurrent CVEs in patients with established CVEs, illustrating that Lp(a) level might be a valuable biomarker for risk stratification and prognostic assessment in this high-risk population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-022-00424-9.
format Online
Article
Text
id pubmed-9682694
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-96826942022-11-24 Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study Xu, Na Yao, Yi Jiang, Lin Xu, Jingjing Wang, Huanhuan Song, Ying Yang, Yuejin Xu, Bo Gao, Runlin Yuan, Jinqing Thromb J Research BACKGROUND: It is well established that lipoprotein(a)[Lp(a)] play a vital role in atherosclerosis. Whether Lp(a) can predict recurrence of cardiovascular events (CVEs) in prior CVEs patients is still unclear. We aim to investigate its association with subsequent long-term adverse events in this high-risk population. METHODS: A total of 4,469 patients with prior CVEs history after PCI were consecutively enrolled and categorized according Lp(a) values of < 10 (low), 10 to 30 (medium), and ≥ 30 mg/dL (high). The primary endpoint was MACCE, a composite of all-cause death, myocardial infarction, stroke and unplanned revascularization. RESULTS: During an average of 5.0 years of follow-up, 1,078 (24.1%) and 206 (4.6%) patients experienced MACCE and all-cause death with 134 (3.0%) of whom from cardiac death. The incidence of MACCE, all-cause death and cardiac death were significantly higher in the high Lp(a) group (p < 0.05). After adjustment of confounding factors, high Lp(a) level remained an independent risk factor for MACCE (adjusted HR 1.240, 95%CI 1.065–1.443, p = 0.006), all-cause death (adjusted HR 1.445, 95%CI 1.023–2.042, p = 0.037) and cardiac death (adjusted HR 1.724, 95%CI 1.108–2.681, p = 0.016). This correlation remained significant when treated as a natural logarithm-transformed continuous variable. This finding is relatively consistent across subgroups and confirmed again in two sensitivity analyses. CONCLUSIONS: Our present study confirmed that Lp(a) was an independent predictor for recurrent CVEs in patients with established CVEs, illustrating that Lp(a) level might be a valuable biomarker for risk stratification and prognostic assessment in this high-risk population. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12959-022-00424-9. BioMed Central 2022-11-21 /pmc/articles/PMC9682694/ /pubmed/36414932 http://dx.doi.org/10.1186/s12959-022-00424-9 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Xu, Na
Yao, Yi
Jiang, Lin
Xu, Jingjing
Wang, Huanhuan
Song, Ying
Yang, Yuejin
Xu, Bo
Gao, Runlin
Yuan, Jinqing
Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title_full Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title_fullStr Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title_full_unstemmed Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title_short Lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-PCI: five-year findings from a large single center cohort study
title_sort lipoprotein(a) predicts recurrent cardiovascular events in patients with prior cardiovascular events post-pci: five-year findings from a large single center cohort study
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9682694/
https://www.ncbi.nlm.nih.gov/pubmed/36414932
http://dx.doi.org/10.1186/s12959-022-00424-9
work_keys_str_mv AT xuna lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT yaoyi lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT jianglin lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT xujingjing lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT wanghuanhuan lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT songying lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT yangyuejin lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT xubo lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT gaorunlin lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy
AT yuanjinqing lipoproteinapredictsrecurrentcardiovasculareventsinpatientswithpriorcardiovasculareventspostpcifiveyearfindingsfromalargesinglecentercohortstudy